Register for a VYVGART
(You)niversity Program

First-of-Its-Kind Treatments

You are invited to VYVGART (You)niversity, an educational program, sponsored by argenx. Join us for free live and virtual programs across the U.S. to hear from health care professionals about treatments for adults with anti-acetylcholine receptor (anti-AChR) antibody positive generalized myasthenia gravis (gMG). Whether you’re newly diagnosed or further along on your treatment journey, we’d love to see you there! Care partners, friends, and family members are also welcome.

You can also register for a program by calling (844) 4-VYV-YOU.


*Indicates a required field

*By checking this box, you certify that you are at least 18 years old and authorize argenx US, Inc., its affiliates, and companies working with argenx to use your contact information and health information to contact you by direct mail, email, telephone, and autodialed text message for marketing purposes, such as to provide you with information, offers, and promotions regarding anti-acetylcholine receptor antibody positive generalized myasthenia gravis, argenx products and programs, to conduct market research or surveys, and to use your information to develop future products, services, and programs. You understand that you may withdraw your authorization provided above by emailing [email protected] or following the unsubscribe instructions on the communication. Unless you withdraw this authorization, it will remain effective for two years. Copies of this authorization may be obtained by emailing [email protected].


By submitting this form, I verify that I am 18 years of age or older.

Thank you for registering for a VYVGART (You)niversity Program

You will be receiving an email confirming registration and next steps.

There was a problem

Please check your information and try again

Return to form


What is the most important information I should know about VYVGART (efgartigimod alfa-fcab) for intravenous (IV) infusion and VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO may cause serious side effects, including:

  • Infection. VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. More patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts. The majority of infections and observed lower white blood cell counts were mild to moderate in severity. Your healthcare provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART or VYVGART HYTRULO. Tell your healthcare provider if you have any history of infections. Tell your healthcare provider right away if you have signs or symptoms of an infection during treatment with VYVGART or VYVGART HYTRULO such as fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. If a serious infection occurs, your doctor will treat your infection and may even stop your VYVGART or VYVGART HYTRULO treatment until the infection has resolved.
  • Undesirable immune reactions (hypersensitivity reactions). VYVGART and VYVGART HYTRULO can cause the immune system to have undesirable reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. In clinical studies, the reactions were mild or moderate and occurred within 1 hour to 3 weeks of administration, and the reactions did not lead to treatment discontinuation. Your healthcare provider should monitor you during and after treatment and discontinue VYVGART or VYVGART HYTRULO if needed. Tell your healthcare provider immediately about any undesirable reactions to VYVGART or VYVGART HYTRULO.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • Have a history of infection or you think you have an infection.
  • Have received or are scheduled to receive a vaccine (immunization). Discuss with your healthcare provider whether you need to receive age-appropriate immunizations before initiation of a new treatment cycle with VYVGART or VYVGART HYTRULO. The use of vaccines during treatment with VYVGART or VYVGART HYTRULO has not been studied, and the safety with live or live-attenuated vaccines is unknown. Administration of live or live-attenuated vaccines is not recommended during treatment with VYVGART or VYVGART HYTRULO.
  • Are pregnant or plan to become pregnant and are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the common side effects of VYVGART and VYVGART HYTRULO?

The most common side effects of efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART and VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

Please see the full Prescribing Information for VYVGART and the full Prescribing Information for VYVGART HYTRULO, and talk to your doctor.

What is VYVGART® for intravenous (IV) infusion and what is VYVGART® HYTRULO for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).